It's hard to believe it's been a full year since Abbott closed its acquisition of Alere, considering what a contentious deal it was and how hard Abbott fought last year to get out of it.

Thermo Fisher Scientific said recently that its third quarter revenues grew 16 percent, driven by growth across its four business segments.

Recently, CEC and WuXi AppTec announced the establishment of a joint venture company, Zhongdian Yaoming, to jointly cultivate the health care big data industry.

Illumina reported recently that its revenues for the third quarter grew 20 percent year over year, driven by growth across its sequencing and microarray products.

NeoGenomics recently announced a definitive agreement to acquire clinical oncology laboratory Genoptix for $125 million in cash and 1 million shares of NeoGenomics' stock.

GeneWiz, Nashville Biosciences Collaborate to Combine NGS Services, Biobank DNA Samples

Roche said recently that its diagnostics division revenues grew 6 percent in the first nine months of 2018, driven mainly by growing demand for its immunodiagnostics solutions.

Thermo Fisher Scientific announced recently that it has received CE-IVD marking for its Oncomine Dx Target Test.

Abbott recently said that its Diagnostics business grew sales 43 percent year over year.

The global Point of Care (POC) hematology diagnostics market is expected to grow at a CAGR of close to 9% over the forecast period 2018-2022 to reach a value of USD 2.7 billion by 2022

The global hemostasis/coagulation analyzers market was valued at USD 3.65 billion in 2017 and is expected to grow at a CAGR of 9.9% over the period 2018 to 2026 to reach USD 9.55 billion by 2026, driven mainly by the growing incidence of blood disorders.

A clinical assay from Zeesan Biotech to detect and identify 14 high-risk genotypes of human papillomavirus has been approved by the China State Food and Drug Administration, company announced recently.

The global medical gas analyzers market was valued at USD 235 million in 2017 and is expected to grow at a CAGR of 4.1% from 2018 to 2025 to reach USD 325 million by 2025

BioMérieux reported today that its third quarter revenues grew 7 percent year over year driven in part by strong growth in its molecular biology clinical applications.

Expedeon reported today a 106 percent jump in its second quarter revenues as the biological products and services company wrapped up the integration of several recent acquisitions.